The pharmacotherapy of urothelial carcinoma (UC) has undergone a paradigm shift from conventional chemotherapy and BCG to novel agent-based strategies, including immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), moving from later-line to... ...

请注册登录后继续浏览